Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

Amneal Pharmaceuticals, Inc.

AMRX

Filing: SEC 10-Q
Period: Three months ended March 31, 2026
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of Amneal Pharmaceuticals, Inc.. A complete text table follows the diagram.

Amneal Pharmaceutical Revenue Flow

Generic and specialty medicines drive a diversified pharmaceutical platform.

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001723128-26-000020
Filed: Date not recorded
Reviewed: Date not recorded
Status: Individual filing review complete

How to read these figures

Labels and displayed flow values are reported filing values or exact disclosed subtotals.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Amneal reports $722.519M of net revenue for the quarter.

View accessible tables

Financial categories · Three months ended March 31, 2026 · Millions of USD
Category	Stage	Value	Notes
Amneal Pharmaceuticals revenue	1	$723M	$722.519M reported quarterly revenue
Generic and specialty pharmaceuticals	2	$723M	Reported net revenue

Financial flows · Millions of USD
From	To	Value
Amneal Pharmaceuticals revenue	Generic and specialty pharmaceuticals	$723M